Leo Varadkar (Dublin West, Fine Gael) | Oireachtas source

I have read the report which indicates that the cost of the medicine outweighs the benefits by a ratio of 10:1 or even 20:1. When one measures the cost against efficacy, the ratio is 10:1 or 20:1, which, unfortunately, is not a very good figure. One would expect the cost to benefit ratio to be more like 1:1. but, unfortunately, it is 10:1 or 20:1. However, that does not mean that the medicine cannot be approved. It is always possible for the company to come back with new data and new information to demonstrate that the drug is more effective than the experts believe it is.

See this speech in context